PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 7, 2026Cancer Investigation0 citations

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science

View Full Paper
JBJeffrey Mathew BobyNINosakhare Paul IlerhunmwuwaJBJame Mathew Benny

Key Points

  • To evaluate the effectiveness of KRAS p.G12C inhibitors in treating metastatic colorectal cancer.
  • Conducted a systematic review of available literature
  • Assessed the efficacy of KRAS-G12C inhibitors
  • Examined the combination with anti-EGFR therapy
  • Compared results to historical data on chemotherapy-refractory CRC
  • Initial data shows promising results for KRAS-G12C inhibitors
  • Combination therapy with anti-EGFR enhances efficacy
  • Supports future frontline trials with these new treatments

Abstract

Initial results of KRAS-G12C inhibitors appear highly promising when they are combined with anti-EGFR therapy compared to historical therapeutic agents indicated for patients with chemotherapy-refractory CRC. Encouraging benefits warrant frontline trials with these novel therapeutics.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Boby et al. (2026) studied this question.

synapsesocial.com/papers/69abc1765af8044f7a4ea11fhttps://doi.org/10.1080/07357907.2026.2636581
Ask AI
Helpful
Bookmark
Share
View Full Paper